Skip to main content

ASEAN Medical Device Directive (AMDD)

What Is the AMDD?​

The ASEAN Medical Device Directive (AMDD) is the regional harmonisation framework developed by ASEAN member states to align medical device regulations across Southeast Asia. Indonesia is one of the AMDD's founding signatories and has incorporated the AMDD's core principles into its national regulatory framework.

The AMDD establishes common frameworks for:

  • Device classification (four-class A–D risk system)
  • Essential Principles of Safety and Performance
  • Quality Management Systems (ISO 13485)
  • Clinical evidence requirements
  • Post-market obligations
  • Common submission dossier template (CSDT)

How the AMDD Shapes Indonesian Regulation​

Indonesia's Permenkes 62/2017 and associated guidance are built on AMDD principles:

AMDD ElementIndonesia Implementation
4-class risk system (A–D)Directly adopted in Permenkes 62/2017
Essential PrinciplesReferenced in CSDT essential principles checklist
ISO 13485 QMSMandatory for imported Class B–D devices
ASEAN CSDTRequired submission format for Regalkes
Clinical evidence requirementsClass-scaled requirements per AMDD guidance
Post-market surveillanceIncorporated in Permenkes 62/2017 obligations

AMDD Member States​

The AMDD applies across the following ASEAN member states:

  • Brunei Darussalam
  • Cambodia
  • Indonesia
  • Lao PDR
  • Malaysia
  • Myanmar
  • Philippines
  • Singapore
  • Thailand
  • Vietnam

However, implementation is not uniform across all member states. Indonesia, Singapore, Malaysia, and Thailand have the most developed regulatory systems aligned with the AMDD. Other members are at varying stages of implementation.

Practical Implications: ASEAN as a Submission Block​

The AMDD harmonisation means that manufacturers can leverage a single CSDT-format dossier as the foundation for submissions across multiple ASEAN markets. This is one of the most significant practical benefits of ASEAN harmonisation for device manufacturers:

  • Prepare one CSDT → adapt for each country (update administrative section, LAR, labeling language)
  • Clinical evidence prepared for one ASEAN submission supports others
  • ISO 13485 and GMP certificates valid across all ASEAN submissions (same scope applies)

The ASEAN CSDT prepared for Singapore (HSA) or Malaysia (MDA) is the closest starting point for an Indonesian submission — requiring primarily administrative adaptation, labeling revision, and verification of consistency with Regalkes formatting requirements.